Category: Covid-19

Page 41«..1020..40414243..5060..»

Judge in civil case over covid-19 fight in Little Rock restaurant chastises defense over evidence submissions … – Arkansas Online

May 15, 2024

Advertisement Advertisement

May 14, 2024 at 8:54 p.m.

by Dale Ellis

Sparks flew Tuesday in federal court as Chief U.S. District Judge Kristine G. Baker threatened to sanction attorneys defending Saltgrass Arkansas in a lawsuit filed by a Little Rock couple claiming the restaurant was negligent in failing to head off a June 2020 brawl that broke out over covid-19 restrictions.

The...

Original post:

Judge in civil case over covid-19 fight in Little Rock restaurant chastises defense over evidence submissions ... - Arkansas Online

Nursing Homes Wield Pandemic Immunity Laws To Duck Wrongful Death Suits – Kaiser Health News

May 15, 2024

By Fred Schulte May 14, 2024

In early 2020, with reports of covid-19 outbreaks making dire headlines, Trever Schapers worried about her fathers safety in a nursing home in Queens.

She had delighted in watching her dad, John Schapers, blow out the candles on his 90th birthday cake that February at the West Lawrence Care Center in the New York City borough. Then the home went into lockdown.

Soon her father was dead. The former union painter spiked a fever and was transferred to a hospital, where he tested positive for covid, his daughter said, and after two weeks on a ventilator, he died in May 2020.

But when Trever Schapers sued the nursing home for negligence and wrongful death in 2022, a judge dismissed the case, citing a New York state law hastily passed early in the pandemic. It granted immunity to medical providers for harm or damages from an act or omission in treating or arranging care for covid. She is appealing the decision.

I feel that families are being ignored by judges and courts not recognizing that something needs to be done and changed, said Schapers, 48, who works in the medical field. There needs to be accountability.

The nursing home did not return calls seeking comment. In a court filing, the home argued that Schapers offered no evidence that the home was grossly negligent in treating her father.

More than four years after covid first raged through many U.S. nursing homes, hundreds of lawsuits blaming patient deaths on negligent care have been tossed out or languished in the courts amid contentious legal battles.

Even some nursing homes that were shut down by health officials for violating safety standards have claimed immunity against such suits, court records show. And some families that allege homes kept them in the dark about the health of their loved ones, even denying there were cases of covid in the building, have had their cases dismissed.

Schapers alleged in a complaint to state health officials that the nursing home failed to advise her that it had admitted covid-positive patients from a nearby hospital in March 2020. In early April, she received a call telling her the facility had some covid-positive residents.

The call I received was very alarming, and they refused to answer any of my questions, she said.

About two weeks later, a social worker called to say that her father had a fever, but the staff did not test him to confirm covid, according to Schapers complaint.

The industry says federal health officials and lawmakers in most states granted medical providers broad protection from lawsuits for good faith actions during the health emergency. Rachel Reeves, a senior vice president with the American Health Care Association, an industry trade group, called covid an unprecedented public health crisis brought on by a vicious virus that uniquely targeted our population.

In scores of lawsuits, however, family members allege that nursing homes failed to secure enough protective gear or tests for staffers or residents, haphazardly mixed covid-positive patients with other residents, failed to follow strict infection control protocols, and brazenly misled frightened families about the severity of covid outbreaks among patients and staff.

They trusted these facilities to take care of loved ones, and that trust was betrayed, said Florida attorney Lindsey Gale, who has represented several families suing over covid-related deaths.

The grieving process people had to go through was horrible, Gale said.

A Deadly Toll

KFF Health News found that more than 1,100 covid-related lawsuits, most alleging wrongful death or other negligent care, were filed against nursing homes from March 2020 through March of this year.

While theres no full accounting of the outcomes, court filings show that judges have dismissed some suits outright, citing state or federal immunity provisions, while other cases have been settled under confidential terms. And many cases have stalled due to lengthy and costly arguments and appeals to hash out limits, if any, of immunity protection.

In their defense, nursing homes initially cited the federal Public Readiness and Emergency Preparedness Act, which Congress passed in December 2005. The law grants liability protection from claims for deaths or injuries tied to vaccines or medical countermeasures taken to prevent or treat a disease during national emergencies.

The PREP Act steps in once the secretary of Health and Human Services declares a public health emergency, which happened with covid on March 17, 2020. The emergency order expired on May 11, 2023.

The law carved out an exception for willful misconduct, but proving it occurred can be daunting for families even when nursing homes have long histories of violating safety standards, including infection controls.

Governors of at least 38 states issued covid executive orders, or their legislatures passed laws, granting medical providers at least some degree of immunity, according to one consumer groups tally. Just how much legal protection was intended is at the crux of the skirmishes.

Nursing homes answered many negligence lawsuits by getting them removed from state courts into the federal judicial system and asking for dismissal under the PREP Act.

For the most part, that didnt work because federal judges declined to hear the cases. Some judges ruled that the PREP Act was not intended to shield medical providers from negligence caused by inaction, such as failing to protect patients from the coronavirus. These rulings and appeals sent cases back to state courts, often after long delays that left families in legal limbo.

These delays have been devastating, said Jeffrey Guzman, a New York City attorney who represents Schapers and other families. He said the industry has fought tooth and nail trying to fight these people getting their day in court.

Empire State Epicenter

New York, where covid hit early and hard, is ground zero for court battles over nursing home immunity.

Relatives of residents have filed more than 750 negligence or wrongful death cases in New York counties since the start of the pandemic, according to court data KFF Health News compiled using the judicial reporting service Courthouse News Service. No other area comes close. Chicagos Cook County, a jurisdiction where private lawyers for years have aggressively sued nursing homes alleging poor infection control, recorded 121 covid-related cases.

Plaintiffs in hundreds of New York cases argue that nursing homes knew early in 2020 that covid would pose a deadly threat but largely failed to gird for its impact. Many suits cite inspection reports detailing chronic violations of infection control standards in the years preceding the pandemic, court records show. Responses to this strategy vary.

Different judges take different views, said Joseph Ciaccio, a New York lawyer who has filed hundreds of such cases. Its been very mixed.

Lawyers for nursing homes counter that most lawsuits rely on vague allegations of wrongdoing and boilerplate claims that, even if true, dont demonstrate the kind of gross negligence that would override an immunity claim.

New York lawmakers added another wrinkle by repealing the immunity statute in April 2021 after Attorney General Letitia James noted the law could give nursing homes a free pass to make financially motivated decisions to cut costs and put patients at risk.

So far, appeals courts have ruled lawmakers didnt specify that the repeal should be made retroactive, thus stymying many negligence cases.

So these cases are all wasting the courts time and preventing cases that arent barred by immunity statutes from being resolved sooner and clogging up the court system that was already backlogged from COVID, said attorney Anna Borea, who represents nursing homes.

Troubled Homes Deflect Suits

Some nursing homes that paid hefty fines or were ordered by health officials to shut down at least temporarily because of their inadequate response to covid have claimed immunity against suits, court records show.

Among them is Andover Subacute and Rehabilitation nursing home in New Jersey, which made national headlines when authorities found 17 bodies stacked in a makeshift morgue in April 2020.

Federal health officials fined the facility $220,235 after issuing a critical 36-page report on covid violations and other deficiencies, and the state halted admissions in February 2022.

Yet the home has won court pauses in at least three negligence lawsuits as it appeals lower court rulings denying immunity under the federal PREP Act, court records show. The operators of the home could not be reached for comment. In court filings, they denied any wrongdoing.

In Oregon, health officials suspended operations at Healthcare at Foster Creek, calling the Portland nursing home a serious danger to the public health and safety. The May 2020 order cited the homes consistent inability to adhere to basic infection control standards.

Bonnie Richardson, a Portland lawyer, sued the facility on behalf of the family of Judith Jones, 75, who had dementia and died in April 2020. Jones was among dozens of covid-related deaths at that home.

It was a very hard-fought battle, said Richardson, who has since settled the case under confidential terms. Although the nursing home claimed immunity, her clients wanted to know what happened and to understand why. The owners of the nursing home provided no comment.

No Covid Here

Many families believe nursing homes misled them about covids relentless spread. They often had to settle for window visits to connect with their loved ones.

Relatives of five patients who died in 2020 at the Sapphire Center for Rehabilitation and Nursing in the Flushing neighborhood in Queens filed lawsuits accusing the homes operators of keeping them in the dark.

When they phoned to check on elderly parents, they either couldnt get through or were told there was no COVID-19 in the building, according to one court affidavit.

One woman grew alarmed after visiting in February 2020 and seeing nurses wearing masks below their noses or under their chin, according to a court affidavit.

The woman was shocked when the home relayed that her mother had died in April 2020 from unknown causes, perhaps from depression and not eating, according to her affidavit.

A short time later, news media reported that dozens of Sapphire Center residents had died from the virus her 85-year-old mother among them, she argued in a lawsuit.

The nursing home denied liability and won dismissal of all five lawsuits after citing the New York immunity law. Several families are appealing. The nursing homes administrator declined to comment.

Broadening Immunity

Nursing home operators also have cited immunity to foil negligence lawsuits based on falls or other allegations of substandard care, such as bedsores, with little obvious connection to the pandemic, court records show.

The family of Marilyn Kearney, an 89-year-old with a history of dementia and falls, sued the Watrous Nursing Center in Madison, Connecticut, for negligence. Days after she was admitted in June 2020, she fell in her room, fracturing her right hip and requiring surgery, according to court filings.

She died at a local hospital on Sept. 16, 2020, from sepsis attributed to dehydration and malnutrition, according to the suit.

Her family argued that the 45-bed nursing home failed to assess her risk of falling and develop a plan to prevent that. But Watrous fired back by citing an April 2020 declaration by Connecticut Gov. Ned Lamont, a Democrat, granting health care professionals or facilities immunity from any injury or death alleged to have been sustained because of the individuals or health care facilitys acts or omissions undertaken in good faith while providing health care services in support of the states COVID-19 response.

Watrous denied liability and, in a motion to dismiss the case, cited Lamonts executive order and affidavits that argued the home did its best in the throes of a public health crisis, the likes of which had never been seen before. The operators of the nursing home, which closed in July 2021 because of covid, did not respond to a request for comment. The case is pending.

Attorney Wendi Kowarik, who represents Kearneys family, said courts are wrestling with how much protection to afford nursing homes.

Were just beginning to get some guidelines, she said.

One pending Connecticut case alleges that an 88-year-old man died in October 2020 after experiencing multiple falls, sustaining bedsores, and dropping more than 30 pounds in the two months he lived at a nursing home, court records state. The nursing home denied liability and contends it is entitled to immunity.

So do the owners of a Connecticut facility that cared for a 75-year-old woman with obesity who required a lift to get out of bed. She fell on April 26, 2020, smashing several teeth and fracturing bones. She later died from her injuries, according to the suit, which is pending.

I think it is really repugnant that providers are arguing that they should not be held accountable for falls, pressure sores, and other outcomes of gross neglect, said Richard Mollot, executive director of the Long Term Care Community Coalition, which advocates for patients.

The government did not declare open season on nursing home residents when it implemented COVID policies, he said.

Protecting the Vulnerable

Since early 2020, U.S. nursing homes have reported more than 172,000 residents deaths, according to Centers for Medicare & Medicaid Services data. Thats about 1 in 7 of all recorded U.S. covid deaths.

As it battles covid lawsuits, the nursing home industry says it is struggling to recover due to ongoing labor shortages, inflation, and chronic government underfunding, according to Reeves, the trade association executive.

She said the American Health Care Association has advocated for reasonable, limited liability protections that defend staff and providers for their good faith efforts during the pandemic.

Caregivers were doing everything they could, Reeves said, often with limited resources and ever-changing information, in an effort to protect and care for residents.

But patients advocates remain wary of policies that might bar the courthouse door against grieving families.

I dont think we want to continue to enact laws that reward nursing homes for bad care, said Sam Brooks, of the Coalition for the Protection of Residents of Long-Term Care Facilities, a patient advocacy group.

We need to keep that in mind if, God forbid, we have another pandemic, Brooks said.

Bill Hammond, a senior fellow at the Empire Center for Public Policy, a nonpartisan New York think tank, said policymakers should focus on better strategies to protect patients from infectious outbreaks, rather than leaving it up to the courts to sort out liability years later.

There is no serious effort to have that conversation, Hammond said. I think thats crazy.

We encourage organizations to republish our content, free of charge. Heres what we ask:

You must credit us as the original publisher, with a hyperlink to our kffhealthnews.org site. If possible, please include the original author(s) and KFF Health News in the byline. Please preserve the hyperlinks in the story.

Its important to note, not everything on kffhealthnews.org is available for republishing. If a story is labeled All Rights Reserved, we cannot grant permission to republish that item.

Have questions? Let us know at KHNHelp@kff.org

Excerpt from:

Nursing Homes Wield Pandemic Immunity Laws To Duck Wrongful Death Suits - Kaiser Health News

Secretory IgA and course of COVID-19 in patients receiving a bacteria-based immunostimulant agent in addition to … – Nature.com

May 15, 2024

Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181, 271280. https://doi.org/10.1016/j.cell.2020.02.052 (2020).

Article PubMed PubMed Central Google Scholar

Chuchalin, A. G., Svitich, O. A., & Kostinov, M. P. Mucosal immunity in patients with COVID-19: treatment and rehabilitation. Monograph. 128 (Moscow, MDV Group, 2022)

Schaad, U. B. Prevention of pediatric respiratory tract infections: emphasis on the role of OM-85. Eur. Respir. Rev. 14, 7477. https://doi.org/10.1183/09059180.05.00009506 (2005).

Article Google Scholar

Korovkina, E. S. & Kostinov, M. P. immunopathological mechanisms of community-acquired pneumonia and chronic obstructive pulmonary disease caused by the infectious pathology of these diseases, and ways of possible immunocorrection. ZHMEI. 2, 100109 (2019).

Google Scholar

Kostinov, M. P., Tatevosov, V. R., Protasov, A. D., Gajnitdinova, V. V. & Sizov, A. V. Vaccination against Staphylococcus aureus and some representatives of the Enterobacteriaceae family in the complex treatment of community-acquired pneumonia of mild course in new recruits. Medicinskij vestnik MVD. CXV(6), 2329 (2021).

Kostinov, M. P., Zorin, N. A., Kazharova, S. V. & Zorina, V. N. Comparative effect of immunomodulators on concentrations of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults. Med. Immunol. 22(4), 791798 (2020).

Article Google Scholar

Kostinov, M. P. et al. The influence of immunomodulators on various markers of the acute phase of inflammation in patients with non-severe community-acquired pneumonia. Tuberculosis Lung Dis. 99(4), 3643 (2021).

Article Google Scholar

Chang, S. Y., Ko, H. J. & Kweon, M. N. Mucosal dendritic cells shape mucosal immunity. Exp. Mol. Med. 46, e84 (2014).

Article CAS PubMed PubMed Central Google Scholar

Chuchalin, A.G. Respiratornaya meditsina. Rukovodstvo 2nd Ed. [Respiratory medicine. Guidelines], vol. 2, 544 (Moscow, Litterra Publ, 2017).

Nikulin, B. A. Otsenka i korrektsiya immunnogo statusa (Assessment and correction of immune status) in Assessment and management of the immune status disorders. 376 (Moscow, GEOTAR-Media Publ., 2007).

Protasov, A. D. et al. The effect of complex vaccination against pneumococcal, hemophilic type b infections and influenza in patients with chronic obstructive pulmonary disease. J. Mikrobiologii, Epidemiologii i Immunobiologii 4, 8084 (2011).

Google Scholar

Ryzhov, A. A., Kostinov, M. P. & Magarshak, O. O. The use of vaccines against pneumococcal and hemophilic type b infections in patients with chronic pathology. Epidemiologiya i Vaktsionoprofilaktika 6(19), 2427 (2004).

Google Scholar

Kostinov, M. P., & Chuchalin, A. G. Clinical immunology guide to respiratory medicine. 2nd ed. 304 (Moscow, Gruppa MDV Publ., 2018).

Avdeev, S. N. et al. Clinical efficacy of mechanical bacterial lysate in the prevention of infectious exacerbations of chronic obstructive pulmonary disease. Terapevticheskiy Arkhiv 92(4), 5763 (2020).

Article CAS Google Scholar

Svitich, O. A. et al. The level of sIgA in nasal secretions and the incidence of complications in hospitalized patients with COVID-19 against an immunotropic drug. ERJ Open Res. 8, 258. https://doi.org/10.1183/23120541.LSC-2022.258 (2022).

Article Google Scholar

Svitich, O. A. et al. Hydrogen effect on the mechanisms of mucosal immunity in patients with COVID-19. Terapevticheskii Arkhiv. 94(3), 372377. https://doi.org/10.26442/00403660.2022.03.201398 (2022).

Article CAS PubMed Google Scholar

Carlo, C. et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J. Allergy Clin. Immunol. 147(2), 545557 (2021).

Article Google Scholar

Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13(577), 2223 (2021).

Article Google Scholar

Kostinov, M. et al. Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms. Drugs Contexts. 12, 1. https://doi.org/10.7573/dic.2022-10-4 (2023).

Article Google Scholar

Chuchalina, A. G., & Yasnecov, V. V. Federal guidelines on the use of medicines (formulary system). Vipusk.XVI., 1016 (Moskow., 2015).

Tajima, Y., Suda, Y. & Yano, K. A case report of SARS-CoV-2 confirmed in saliva specimens up to 37 days after onset: proposal of saliva specimens for COVID-19 diagnosis and virus monitoring. J. Infect. Chemother. 26, 10861089 (2020).

Article CAS PubMed PubMed Central Google Scholar

To, K.K.-W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect. Dis. 20, 565574 (2020).

Article CAS PubMed PubMed Central Google Scholar

Chen, J.H.-K. et al. Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. Emerg. Microbes Infect. 9, 13561359 (2020).

Article ADS CAS PubMed PubMed Central Google Scholar

Bates, D., Maechler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67(1), 148 (2015).

Article Google Scholar

Hartig, F. DHARMa: Residual diagnostics for hierarchical (multi-level/mixed) regression models. R package version 0.4.5. https://CRAN.R-project.org/package=DHARMa (2022).

Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest package: Tests in linear mixed effects models. J. Stat. Softw. 82(13), 126 (2017).

Article Google Scholar

Yoav, B., Krieger, A. M. & Yekutieli, D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. 93(3), 491507 (2006).

Article MathSciNet Google Scholar

Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 183, 169184 (2020).

Article CAS PubMed PubMed Central Google Scholar

Krammer, F. SARS-CoV-2 vaccines in development. Nature. 586, 516527 (2020).

Article ADS CAS PubMed Google Scholar

Mudgal, R., Nehul, S. & Tomar, S. Prospects for mucosal vaccine: Shutting the door on SARS-CoV-2. Hum. Vaccines Immunother. 16, 29212931. https://doi.org/10.1080/21645515.2020.1805992 (2020).

Article CAS Google Scholar

Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent omicron RBD evolution. Nature. 614, 521529 (2023).

ADS CAS PubMed Google Scholar

Zhuang, Z. F. et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: Randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir. Med. 10, 749760 (2022).

Article PubMed PubMed Central Google Scholar

ZhuShoujie, F. et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial November 2023. Lancet Respir. Med. 11(12), S2213-2223. https://doi.org/10.1016/S2213-2600(23)00349-1 (2023).

Article Google Scholar

Tuksin, J. et al. Intranasal administration of RBD nanoparticles confers induction of mucosal and systemic immunity against SARS-CoV-2 vaccines (Basel). 9(7), 768 (2021).

Suloeva, S. V., Kostinov, M. P. & Esman, V. N. Preventive and clinical effect of the use of IRS 19 in children born to HIV-positive women. Epidemiologiya i vakcinoprofilaktika. 1(20), 5456 (2005).

Google Scholar

Kostinov, M. P., Suloeva, S. V., Tarasova, A. A. & Lukushkina, E. F. Mucosal immunity in children with HIV infection and the possibility of its correction. ZHurnal mikrobiologii, epidemiologii i immunobiologii. 2, 7577 (2006).

Google Scholar

Ilenko, L. I. et al. Immunization with vaccines for the prevention of pneumococcal, hemophilic infection and influenza in frequently and long-term ill children with chronic and often recurrent nonspecific infectious pathology of the bronchopulmonary system. Voprosy sovremennoj pediatrii. 5(4), 2730 (2006).

Google Scholar

Foshina, E. P., Polishchuk, V. B., Kostinov, M. P. & Krasnoproshina, L. I. Correction of oral microbiocenosis disorders in children with chronic tonsillitis using topical bacterial lysate. Voprosy sovremennoj pediatrii 6(2), 107109 (2007).

Google Scholar

Chistyakova, E. G. et al. Profilaktika i lechenie ostryh respiratornyh infekcij nosoglotki u bolnyh yunosheskim artritom (Prevention and treatment of acute respiratory infections of the nasopharynx in patients with juvenile arthritis). Voprosy sovremennoj pediatrii 5(6), 4044 (2006).

Google Scholar

Kostinov, M. P. & Ababiya, I. I. Rukovodstvo po vakcinacii i immunoterapii pri LOR-patologii Guidelines for vaccination and immunotherapy in ENT pathology () (Ed. Kostinov, M.P., Ababiya, I.I.) 448 (Gruppa MDV, 2019).

Fbin, T. K., Fejrdy, P. & Csermely, P. Salivary genomics, transcriptomics and proteomics: The emerging concept of the oral ecosystem and their use in the early diagnosis of cancer and other diseases. Curr. Genomics. 9, 1121 (2008).

Article PubMed PubMed Central Google Scholar

Kryukova, N. O., Rakunova, E. B., Kostinov, M. P., Baranova, I. A. & Svitich, O. A. Cekretornyj immunoglobulin A respiratornoj sistemy i COVID-19 (Secretory immunoglobulin A of the respiratory system and COVID-19). Pulmonologiya 31(6), 792798. https://doi.org/10.18093/0869-0189-2021-31-6-792-798 (2021).

Article Google Scholar

Egorova, N. B. & Kurbatova, E. A. Immunotherapeutic concept of the use of microbial antigens in atopy and pathology associated with conditionally pathogenic microflora (using the example of the multicomponent Immunovak-VP-4 vaccine). Med. Immunol. 10(1), 1320. https://doi.org/10.15789/15630625-2008-1-13-20 (2008).

Article Google Scholar

Isho, B. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci. Immunol. 5(52), 5511. https://doi.org/10.1126/sciimmunol.abe5511 (2020).

Article Google Scholar

Fang, L., Zhou, L., Tamm, M. & Roth, M. OM-85 Broncho-Vaxom, a bacterial lysate, reduces SARS-CoV-2 binding proteins on human bronchial epithelial cells. Biomedicines. 9(11), 1. https://doi.org/10.3390/biomedicines9111544 (2021).

Article CAS Google Scholar

View original post here:

Secretory IgA and course of COVID-19 in patients receiving a bacteria-based immunostimulant agent in addition to ... - Nature.com

FDA tells users to throw away Cue Health’s home COVID tests – Fierce Biotech

May 15, 2024

The FDA is recommending that anyone who still has any home COVID tests left from Cue Health should throw them away.

According to the agency, its inspectors discovered that the diagnostics company had made undisclosed changes to its products in the time since receiving a green light from the FDA and that these changes reduced the reliability of the tests to detect SARS-CoV-2 virus.

Do not use any Cue Health COVID-19 Tests for Home and OTC Use that you may still have. Dispose of the entire test cartridge in the household trash, the FDA wrote in its notice to the public and urged users to take a different test if they previously received a negative result but still have symptoms.

The agency also handed Cue a warning letter late last week, which said the modifications the company made to its tests hardware and firmware could result in the device failing earlier than its nine-month expiration date.

Cue said in a May 13statementthat it is evaluating the letter and determining its response, with more information to follow in the next few days. The companys stock fell by about 15% on the news, down to about 12 cents.

Though the San Diego-based Cue was first founded in 2010 with the goal of providing an easier, more portable molecular screener for diseases such as influenza, the arrival of the COVID-19 pandemic kicked its operations into high gear.

The company, a former Fierce 15 winner, raised $100 million in venture capital cash through a June 2020 funding roundamid federal contracts worth hundreds of millions more to help juice its manufacturing capacity, and while inking deals to provide tests to the NBA and Major League Baseball.

The year after, it filed a $200 million Nasdaq IPO with a first-day high of over $22 per share and a valuation approaching $3 billion, with a pledge to expand its catalog far beyond COVID. The company aimed to become a full-service home diagnostic provider for diseases such as the flu and respiratory syncytial virus, as well as sexually transmitted conditions and more.

With its battery-powered, palm-sized reader and single-use PCR cartridges, Cue received emergency COVID authorizations from the FDA for both point-of-care testing by healthcare workers and for use in the home by the general public.

Last summer, it claimed a full de novo clearance from the FDA for its over-the-counter coronavirus testmarking the first at-home test for any respiratory disease, and one celebrated by agency leadership as a trailblazer in a new era of consumer access to diagnostic tests.

However, Cue shortly came under investor pressure, as its share price continued to decline alongside the publics demand for home testsor COVID tests of any kind. Last August, Tarsadia Investments, representing a group of family stockholders that had backed Cue during its pre-pandemic series B round, called on the companys board to launch a strategic review of its business before Cue ran out of money.

In March, the company reported $70.9 million in 2023 revenues, alongside a net loss of $148.4 million.

Earlier this month, the company disclosed in a Securities and Exchange Commission filing the latest in a series of layoffs since January 2023: Cue plans to cut its global workforce by about half, letting go of 230 employees.

Prior to that, the company saw the departure announcements of its co-founder and long-time CEO, Ayub Khattak, in March, followed by its chief financial officer Aasim Javed. Co-founder and Chief Product Officer Clint Sever now serves as CEO.

Cue had previously scheduled its 2024 first-quarter earnings release for May 13, but it has been delayed; its annual general meeting is scheduled for today, May 14.

Read more:

FDA tells users to throw away Cue Health's home COVID tests - Fierce Biotech

Former West Virginia health official gets probation in COVID-19 payment investigation – The Associated Press

May 15, 2024

CHARLESTON, W.Va. (AP) A former West Virginia state health official was sentenced Monday to one year of probation for lying about whether or not he verified vendor invoices from a company claiming to have conducted COVID-19 tests for the state.

Timothy Priddy was sentenced in federal court for his guilty plea to making a false statement to investigators.

An indictment filed in October charged Priddy with lying to federal agents in August 2022 when he said he verified a vendors invoices for performing COVID-19 tests as part of a back-to-school program before approving them. Priddy knew his statements were false because he made no such verification efforts, according to prosecutors.

Priddy, 49, of Buffalo, West Virginia, had faced up to five years in prison and a $250,000 fine.

Priddy, who held various managerial positions with the state Bureau for Public Healths Center for Threat Preparedness, left his job the day the indictment was announced.

Prosecutors said federal investigators were trying to determine whether one or more vendors providing COVID-19 tests and mitigation services to the state overbilled or otherwise received federal payments they shouldnt have through the state Department of Health and Human Resources. Investigators focused on a vendor that submitted invoices approved by Priddy for payments exceeding $34 million.

Prosecutors said the vendor reported the results of about 49,000 COVID-19 tests between October 2020 and March 2022 but submitted invoices reflecting the cost of about 518,000 test kits. The indictment did not name the vendor but said the company was from out of state and provided test kits, laboratory analysis and held community testing events throughout West Virginia.

Vendors were required to report test results so officials would have accurate information about the number of COVID-19 infections and any geographical hot spots, the indictment said.

The West Virginia Health Department has said that a contract with the company ended in October 2022 and that the agency cooperated fully with federal investigators.

U.S. Attorney Will Thompson said significant questions remain concerning the legitimacy of the vendors invoices but there is no evidence that Priddy lied to protect the vendor or further its business.

Instead, it appears that Mr. Priddy lied to hide his own dereliction of duty, Thompson said.

Read more here:

Former West Virginia health official gets probation in COVID-19 payment investigation - The Associated Press

COVID-19 led to changing views on wearable tech, Northwestern study finds – CBS Chicago

May 15, 2024

Watch CBS News

It appears the COVID-19 pandemic is changing the way some think when it comes to monitoring their health. A study led by Northwestern University researchers reveals that some in underserved communities are becoming more comfortable with wearable tech, such as smart watches and heartrate monitors.

Be the first to know

Get browser notifications for breaking news, live events, and exclusive reporting.

Read the original post:

COVID-19 led to changing views on wearable tech, Northwestern study finds - CBS Chicago

What is the new FLiRT variant of the Covid virus, and should you worry? – The Indian Express

May 15, 2024

The new coronavirus variant called KP.2 nicknamed FLiRT that has been linked to rising cases of Covid-19 in the United States, United Kingdom, and South Korea, has been in circulation in India since November 2023, genomic surveillance data show. About 250 KP.2 sequences have been reported so far by INSACOG, the countrys genome sequencing consortium.

KP.2 is a descendant of the JN.1 variant of the virus. It is a sub-variant of the Omicron lineage with new mutations. FLiRT, the nickname of KP.2, is based on the letters representing two immune escape mutations that allow the virus to evade antibodies.

Genomic scientist Dr Vinod Scaria said: These two mutations on the spike protein disrupt the major sites on the spike protein where antibodies bind and neutralise the SARS-CoV-2 virus. These mutations allow the virus to escape antibodies.

A little more than half of the 250 KP.2 genomes sequenced by INSACOG 128 sequences were from Maharashtra. The highest number of KP.2 sequences were found in March.

India has been reporting the highest proportion of KP.2 sequences in the world, global data show. KP.2 sequences made up 29% of Covid-19 sequences uploaded by India to the Global Initiative on Sharing All Influenza Data (GISAID), the worlds largest repository of these sequences, over the last 60 days.

However, JN.1 continues to be the dominant variant of SARS-CoV-2 in the country. There were 679 active cases of Covid-19 in India on May 14, according to Union Health Ministry data, and one death in Delhi was attributed to the disease.

FLiRT is characterised by its ability to evade immunity from vaccines and previous infections. Its symptoms are similar to those of earlier variants, including fever, cough, fatigue, and digestive issues.

Experts are watching the variant closely, but they are not very concerned at the moment. There is no need to worry, Dr Anurag Agarwal, dean of the Trivedi School of Biosciences at Ashoka University, said. These [immune escape] mutations [like the ones on FLiRT] have been seen before.

The US Centers for Disease Control and Prevention (CDC) notes that there are currently no indicators suggesting that KP.2 would cause more severe illness than other strains.

Yes, FLiRT has a heightened transmission rate and, like its parent JN.1, it is likely to drive a wave of infections, Dr Scaria said. Also, the infections are likely to spread silently because without severe symptoms, most people are unlikely to get themselves tested.

Dr Rajesh Chawla, senior consultant, pulmonology and critical care at Indraprastha Apollo Hospital in Delhi, said given the likelihood of easy spread of the virus through respiratory droplets, there is need to take stringent precautions, especially for those with a compromised immune system.

Senior citizens are vulnerable to severe illness due to factors such as age-related physiological changes, decreased immune function, and the presence of comorbidities. Research indicates that adults aged 60 and older, especially those with pre-existing medical conditions like heart disease, lung disease, diabetes, or cancer, are more likely to experience severe and potentially fatal Covid-19 infections compared to other age groups.

People who are 65 and older, or immunocompromised, and pregnant women are the most vulnerable.

This variant, like many of its Omicron predecessors, mainly affects the upper respiratory tract. There is no documented difference in presentations, Dr Scaria said.

Dr Chawla said that those affected report fever or chills, cough, sore throat, congestion or runny nose, headache, muscle aches, difficulty in breathing, fatigue, loss of taste or smell, brain fog, feeling less wakeful and aware, and gastro-intestinal symptoms including upset stomach, mild diarrhoea, and vomiting.

Hospitalisation rates for patients with these symptoms were not higher than usual, Dr Chawla said.

How can infection be prevented?

Preventive measures are the same as the ones that have been advised since the beginning of the Covid outbreak four years ago. Social distancing and the use of well-fitting respirators like N95s or KN95s in indoor public settings protect against all variants of the Covid-19 virus.

Increased air flow and filtration in indoor spaces also help reduce the concentration of virus particles. Vulnerable groups and those living in areas where the infection is in circulation should be especially careful.

Most Covid-19 vaccines available in India are aimed at the original variant of the virus, so additional shots are unlikely to help.

In late April, the WHOs Covid vaccine advisory group advised the use of JN.1 lineage as the antigen for upcoming vaccine formulations, as the FLiRT variants are within the JN.1 family. However the Indian vaccines are not updated with the JN.1 variant, and therefore booster doses in India are unlikely to be effective, Dr Scaria said.

Dr Agarwal said that most Indians do not need a booster because they have probably already had repeated infections, including silent infections with JN.1.

The Indian Express Pvt Ltd

Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the governments management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the countrys space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia Universitys Dart Centre. Dutt has a Bachelors Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More

First uploaded on: 14-05-2024 at 19:39 IST

View original post here:

What is the new FLiRT variant of the Covid virus, and should you worry? - The Indian Express

Dr. Eileen de Villa is resigning as Toronto’s medical officer of health – CP24

May 15, 2024

The doctor who led Toronto through the COVID-19 pandemic as the citys top public health official is stepping down.

Dr. Eileen de Villa announced her resignation in a video message posted to social media on Tuesday.

Sporting one of her signature scarves, de Villa said that it has been her distinct honour and privilege to serve as Torontos Medical Officer of Health and lead Canadas largest local public health unit since first being appointed to the role in 2017.

To you, the people of Toronto, I am incredibly grateful, deeply, deeply grateful for the privilege of having served as your medical officer of health for these last several years, said de Villa, who will be concluding her duties on Dec. 31.

And I am incredibly grateful as well, for the positive impact we've had on the health of this city. It has truly been the honor and the privilege of a lifetime to work alongside my remarkable colleagues here at Toronto Public Health and with other community providers, whether it's within city divisions, or other leaders and health providers throughout the city. And as well members of communities throughout the entire city of Toronto. I cannot thank you enough for all your support over these years. And for everything that we have done together.

De Villa, who is 55, called the last eight years a remarkable time.

Together with the team at Toronto Public Health, we've navigated significant challenges, she said, noting that throughout it all TPHs unwavering focus has been on protecting the health and well being of Torontonians.

Everything from the COVID 19 pandemic, to changes in public health funding to the drug toxicity epidemic and the mental health crisis that is currently in our midst.

De Villa went on to note that her decision to step down was not taken lightly and comes after several months of heartfelt discussions with her family.

She said that shes ready to embark on the next chapter of her professional life and to spend more time with my family.

De Villa, who is an Adjunct Professor at the Dalla Lana School of Public Health at the University of Toronto, has a husband and three children.

Torontos top doc also said that she feels that the city is in a good position to transition to a new medical officer of health to lead Toronto Public Health, as we are stabilizing as an organization after the COVID 19 pandemic.

Nonetheless, she did acknowledge that Toronto continues to face a number of public health challenges, particularly emerging from the events of the last few years and said she and her team will have much work to accomplish over the next six months.

And I want to assure you that in the time that's left, I will continue to press on and make sure that together with the organization, we will continue to do our very best to meet the health needs of Torontonians, she said.

De Villa said that shes expects TPH will provide details about its next steps for selecting a new medical officer of health in the near future.

Toronto Public Health has an incredible and strong team in place. And I'm confident that they will continue to lead in public health excellence, she said.

I wish you all the very, very best. And I know that my colleagues here at Toronto Public Health will continue to do their utmost as they always do to safeguard, protect and promote the health of this great city.

In a statement, Coun. Chris Moise said that he received de Villas letter of resignation with mixed emotions.

As Chair of the Board of Health, I have had the privilege of working closely with Dr. de Villa, and I am deeply grateful for her unwavering support, guidance, and willingness to collaborate. While her departure saddens me, I am excited for the opportunities that await her, and I am confident she will leave Toronto Public Health well-positioned for continued success, wrote Moise, who called de Villas contributions to the City of Toronto immeasurable and said that over the last eight years she has navigated us through unprecedented challenges, most notably the COVID-19 pandemic.

It was an incredibly difficult experience for everyone, especially Toronto Public Health staff, but Dr. De Villa consistently delivered critical updates with a reassuring voice that said it is going to be okay, even when the path ahead seemed uncertain, the Toronto Centre rep said.

Although Dr. de Villa announced her retirement today, she will continue shepherding us through this transitional period until the year's end, ensuring a smooth transition.

Moise said that by the end of de Villas tenure TPHs new Strategic Plan will be complete, The Works relocation will be nearly complete, and that a comprehensive transition plan will be implemented for her successor.

He said that he intends to bring forward a motion at the May 27 BOH meeting to form a search committee for the citys next medical officer of health.

Dr. de Villa, thank you for your service to the City of Toronto. Your leadership in building a healthier, more equitable city has made a lasting impact, and your dedication to public health will be remembered and celebrated. Wishing you all the best in your future endeavours, Moise said.

Continue reading here:

Dr. Eileen de Villa is resigning as Toronto's medical officer of health - CP24

John Krasinski Says the COVID-19 Pandemic’s Effect on His Kids Inspired ‘IF’ Imaginary Friends Movie | Video – Yahoo Entertainment

May 15, 2024

John Krasinski sat down with Jimmy Fallon on Friday to discuss his newest movie IF, which he said was partly inspired by the impact the COVID-19 pandemic had on his two children, Hazel and Violet. He explained that during the pandemic, Genuinely, I saw their light starting to go out, and they started playing fewer and fewer imaginary games.

Krasinski said he always wanted to make a film for his children, but wasnt sure what story would work the best. He had the idea to tie in imaginary friends like 10 years ago, but nothing was cemented. Over time, the imaginary world he watched his and wife Emily Blunts daughters disappear into inspired him.

I used to just stand in the doorway and watch my kids disappear in this magical world that we, as parents, arent allowed in, he explained. And it wasnt just like the joy that was on their face, it was how authentic they were they could be anything they wanted in this world. And I said, Em, that would make a great movie.'

Krasinski added that he wrote the movie in part to, in turn, inspire his daughters. Im writing this movie right now to prove to you that magical world is always there and you can always go back, he said that he told them.

The movie stars Cailey Fleming as Bea, a young girl who has discovered she can see peoples imaginary friends and makes it her mission to reconnect forgotten imaginary friends, or IFs, with their kids.

Krasinski had plenty of praise for Fleming. He said, Ill be honest, the whole movie works because of her, because you have this idea and its hugely ambitious, and it can go around many ways.

Watch the full interview with John Krasinski from The Tonight Show With Jimmy Fallon in the video above.

The post John Krasinski Says the COVID-19 Pandemics Effect on His Kids Inspired IF Imaginary Friends Movie | Video appeared first on TheWrap.

More here:

John Krasinski Says the COVID-19 Pandemic's Effect on His Kids Inspired 'IF' Imaginary Friends Movie | Video - Yahoo Entertainment

TB-COVID co-infections increasingly common, tied to worse outcomes, data show – University of Minnesota Twin Cities

May 15, 2024

Iuliia Mikhalitskaia/ iStock

A new meta-analysis of 17 studies reveals that tuberculosis (TB) and COVID-19 co-infection are becoming increasingly prevalent around the world, with death rates gradually declining but remaining higher than COVID-19 infection alone. The study was published yesterday in PLOS Neglected Tropical Diseases.

The 17 studies were conducted in 38 countries or regions, spanning both high- and low-TB prevalence areas. Sixteen of the studies were single-country studies. The other study included TB-COVID patients from 172 centers in 34 countries as part of the TB/COVID-19 Global Study Group in 2022.

Two studies estimated TB-COVID joint infection prevalence, one conducted in Western Cape Province, South Africa, (prevalence of 0.06%) and one in California (prevalence of 0.02%). In all studies, patients were treated with known TB drugs, including rifampicin, isoniazid, ethambutol, and pyrazinamide. The authors found no studies that could provide specific guidance on the best practices for managing TB-COVID co-infections.

Patients with both infections were at an increased risk for hospitalization, intensive care unit admission, and death. The estimated fatality rate among hospitalized patients with TB-COVID co-infection was 11.4% (95% confidence interval [CI], 5.6% to 18.8%). Overall fatality rate for patients co-infected was 7.1% (95% CI, 4.0% to 10.8%).

The pooled relative risk of in-hospital fatality was 0.8 (95% CI, 0.18 to 3.68) for TB-COVID patients versus patients with COVID-19 only, the authors found.

Individuals with TB-COVID co-infection are at heightened risk of hospitalization, protracted recovery periods, and accelerated mortality compared to those with sole COVID-19 infections

"Our analysis consistently shows that individuals with TB-COVID co-infection are at heightened risk of hospitalization, protracted recovery periods, and accelerated mortality compared to those with sole COVID-19 infections," the study authors wrote. "Remarkably, we found limited information on the post-COVID-19 condition of co-infected patient."

Read more:

TB-COVID co-infections increasingly common, tied to worse outcomes, data show - University of Minnesota Twin Cities

Page 41«..1020..40414243..5060..»